Ibex Medical Analytics vs Paige (2026)
Both hold an FDA authorization that covers the AI itself on prostate biopsies, used at different points in the read. Ibex's Galen Second Read is 510(k) cleared (K241232, January 2025) to flag biopsies a pathologist has already called benign for another look, on the Philips Ultra Fast Scanner, with Paige Prostate as its predicate. Paige Prostate holds the De Novo authorization (DEN200080, 2021) as an adjunct that flags the area most likely to contain cancer. Ibex also sells breast and gastric solutions, research use only in the United States and CE-IVD marked elsewhere; Paige sells suites across several cancers and foundation models, and has been part of Tempus since August 2025.
- You want AI to review cases after the pathologist has called them benign, as a second read.
- Your security review wants documents in hand: Ibex publishes its business associate addendum, data protection addendum and subprocessor list.
- Results should return into the systems you already use, through partners including Roche, Philips, Proscia and Sectra.
- You want the AI alongside the primary read, pointing to the most suspicious area.
- You want suites across several cancer types and foundation models.
- You already work with Tempus.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Ibex Medical Analytics and Paige are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Ibex Medical Analytics | Paige |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2018 |
| Headquarters | Tel Aviv, Israel | New York, New York, United States |
| Website | ibex-ai.com | paige.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Cancer diagnostics company selling Galen, AI applications that analyze H&E whole slide images for prostate, breast and gastric cancer and return results into laboratories' existing image management and laboratory systems through partners including Roche, Philips, Proscia and Sectra.
Source: AI Health Index, September 2026
Computational pathology company that produced the first FDA authorized AI based digital pathology product: Paige Prostate received De Novo authorization (DEN200080) in September 2021 as an adjunct that flags the area of a digitized prostate biopsy most likely to contain cancer, used with a specified scanner and the company's FullFocus viewer.
Source: AI Health Index, September 2026
Questions buyers ask
How do Ibex Medical Analytics and Paige work with the EHR?
For Ibex Medical Analytics, the 510(k) summary describes the cleared product ingesting slides automatically from the scanner and image management system, with the diagnosis documented in another system such as the LIS.
Paige ships its own viewing and case management layer, the FDA cleared FullFocus viewer and the FullFolio image management system, as a turnkey option, and states that its applications also run inside partner digital pathology platforms, so a laboratory that already runs an image management system need not replace it. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Ibex Medical Analytics and Paige priced and sold?
In Ibex Medical Analytics' case, the company's pages carry no list price, per case or per slide rate, tier structure or worked example for any Galen application, and commercial contact runs through a contact form.
For Paige, the suites and the platform carry no list price, tier structure, per slide or per case rate, or subscription level. Evaluation runs through a trial request and commercial terms through contact with the company, and the platform has been distributed through a cloud marketplace, which can carry standard terms. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Ibex Medical Analytics and Paige handle patient data?
The Data Protection Addendum (last updated February 2026), linked from the trust center, lets Ibex delete customer personal data 21 days after receipt unless a different period is agreed in the purchase confirmation, and requires deletion from Ibex's and its sub-processors' systems at termination or on written request.
Paige's privacy policy is scoped to the company's websites and online services, and the personal information it lists is business and website contact data collected through analytics and marketing tools; it does not describe what happens to the whole slide images a laboratory processes through the Paige Platform or Alba. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Ibex Medical Analytics and Paige cover?
For Ibex Medical Analytics, the company sells Galen for prostate, breast and gastric biopsies and says its models were developed from more than 10 million slides from multiple pathology institutes.
With Paige, the company sells suites for prostate, breast, gastrointestinal and pan cancer pathology to clinical pathology laboratories, and, through Tempus, reaches precision oncology programs. Paige Prostate's authorization names its setting precisely: digitized prostate biopsy images from the Philips Ultra Fast Scanner, viewed in FullFocus, as an adjunct to the pathologist's review. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Each authorization is tied to a named scanner and viewer, so check the one you run. A Breakthrough Device designation on Paige's pan cancer tool is a development status, not an authorization. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.